Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: July 23, 2017
What are the generic sources for cabazitaxel and what is the scope of cabazitaxel patent protection?
Cabazitaxel is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.| Tradenames: | 1 |
| Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: see list | 13 |
| Suppliers / Packagers: see list | 1 |
| Bulk Api Vendors: see list | 31 |
| Clinical Trials: see list | 92 |
| Patent Applications: see list | 56 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see low prices |
| DailyMed Link: | cabazitaxel at DailyMed |
| Applicant | Application No. | Strength | Dosage Form |
| ► Subscribe | ► Subscribe | 20MG/ML(60MG/3ML) | INJECTABLE;INJECTION |
| ► Subscribe | ► Subscribe | 60MG/6ML | INJECTABLE;INJECTION |
| ► Subscribe | ► Subscribe | 40MG/4ML | INJECTABLE;INJECTION |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | JEVTANA KIT | cabazitaxel | SOLUTION;IV (INFUSION) | 201023-001 | Jun 17, 2010 | RX | Yes | Yes | ► Subscribe | ► Subscribe | |||||||||||||||||||
Sanofi Aventis Us | JEVTANA KIT | cabazitaxel | SOLUTION;IV (INFUSION) | 201023-001 | Jun 17, 2010 | RX | Yes | Yes | ► Subscribe | ► Subscribe | |||||||||||||||||||
Sanofi Aventis Us | JEVTANA KIT | cabazitaxel | SOLUTION;IV (INFUSION) | 201023-001 | Jun 17, 2010 | RX | Yes | Yes | 5,847,170*PED | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Sanofi Aventis Us | JEVTANA KIT | cabazitaxel | SOLUTION;IV (INFUSION) | 201023-001 | Jun 17, 2010 | RX | Yes | Yes | 7,241,907*PED | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Sanofi Aventis Us | JEVTANA KIT | cabazitaxel | SOLUTION;IV (INFUSION) | 201023-001 | Jun 17, 2010 | RX | Yes | Yes | 8,927,592*PED | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | JEVTANA KIT | cabazitaxel | SOLUTION;IV (INFUSION) | 201023-001 | Jun 17, 2010 | 6,387,946 | ► Subscribe | ||||||||||||||||||||||
Sanofi Aventis Us | JEVTANA KIT | cabazitaxel | SOLUTION;IV (INFUSION) | 201023-001 | Jun 17, 2010 | 5,438,072 | ► Subscribe | ||||||||||||||||||||||
Sanofi Aventis Us | JEVTANA KIT | cabazitaxel | SOLUTION;IV (INFUSION) | 201023-001 | Jun 17, 2010 | 6,331,635 | ► Subscribe | ||||||||||||||||||||||
Sanofi Aventis Us | JEVTANA KIT | cabazitaxel | SOLUTION;IV (INFUSION) | 201023-001 | Jun 17, 2010 | 6,372,780 | ► Subscribe | ||||||||||||||||||||||
Sanofi Aventis Us | JEVTANA KIT | cabazitaxel | SOLUTION;IV (INFUSION) | 201023-001 | Jun 17, 2010 | 5,698,582 | ► Subscribe | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,232,477 | Methods of preparing new taxoids and pharmaceutical compositions containing them | ► Subscribe | |||||||||||||||||||||||||||
| 6,331,635 | Taxoids, their preparation and pharmaceutical compositions containing them | ► Subscribe | |||||||||||||||||||||||||||
| 5,889,043 | Taxoids, preparation thereof and pharmaceutical Compositions containing same | ► Subscribe | |||||||||||||||||||||||||||
| 6,372,780 | Methods of treating cell lines expressing multidrug resistance P-glycoprotein | ► Subscribe | |||||||||||||||||||||||||||
| 6,187,916 | Process for the preparation of taxane derivatives and .beta.-lactam intermediates therefor | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Taiwan | 201611831 | ► Subscribe | |||||||||||||||||||||||||||
| Taiwan | 394765 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 2013509394 | ► Subscribe | |||||||||||||||||||||||||||
| Mexico | 2012005030 | ► Subscribe | |||||||||||||||||||||||||||
| Malaysia | 136668 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| /2013 | Austria | ► Subscribe | PRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317 | ||||||||||||||||||||||||||
| 0130017 00077 | Estonia | ► Subscribe | PRODUCT NAME: KABASITAKSEEL;REG NO/DATE: K(2011)1888 LOPLIK 17.03.2011 | ||||||||||||||||||||||||||
| 00595 | Netherlands | ► Subscribe | PRODUCT NAME: CABAZITAXEL ACETONAAT; REGISTRATION NO/DATE: EU/1/11/676/001 20110317 | ||||||||||||||||||||||||||
| 2013010 | Lithuania | ► Subscribe | PRODUCT NAME: CABAZITAXELUM; REGISTRATION NO/DATE: EU/1/11/676/001 20110317 | ||||||||||||||||||||||||||
| 172 | Luxembourg | ► Subscribe | PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL) | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,081 other biopharmaceutical professionals who get our Drug Patent Expiration Alerts:
